Skip Nav Destination
Leiden University Medical Centre
Leiden, Netherlands
Dr. Willem E. Fibbe is Emeritus Professor of Hematology and Stem Cell Biology at Leiden University Medical Centre (LUMC) in the Netherlands. He completed his PhD in 1988 (cum laude) on "Interleukin-1 , a regulator of hematopoiesis" and later became Head of Bone Marrow Transplantation and the Department of Immunohematology. He has held various leadership roles at LUMC, was president of the European Hematology Association (EHA) and served on committees for the EMA, WHO, ISEH, NetCord and ASH. He is an active member of the Netherlands Clinical Trial Competent Authority. Dr. Fibbe's research focuses on hematopoietic stem cell biology, regenerative medicine, and cellular therapies. He co-founded the Leiden Regenerative Medicine Platform and is CSO of Starfish Innovations. In 2018, he was named Knight in the Order of the Lion of the Netherlands.
Dana-Farber Cancer Institute
Boston, Massachusetts
Caron Jacobson is an Associate Professor of Medicine at Harvard Medical School, Senior Physician in the lymphoma division at the Dana-Farber Cancer Institute, and the Medical Director of the Immune Effector Cell (IEC) Therapy Program at the Dana-Farber Cancer Institute. She earned her BS from Brown University and MD from Columbia College of Physicians and Surgeons, where she stayed to do her Internal Medicine Residency and Chief Residency before completing her fellowship in hematology and oncology at the joint Dana-Farber/Massachusetts General fellowship program. She is a lymphoma clinical investigator with a focus on cellular immunotherapy for the treatment of lymphoma, and has led several industry-sponsored and investigator-initiated trials of CAR T-cells in lymphoma. As the Medical Director of the IEC program, she oversees both the commercial and research efforts in engineered cellular therapies across the institute, from blood cancers to solid tumors.
Editorial Board
Inaugural Editor-in-Chief
Willem Fibbe, MD, PhDLeiden University Medical Centre
Leiden, Netherlands
Dr. Willem E. Fibbe is Emeritus Professor of Hematology and Stem Cell Biology at Leiden University Medical Centre (LUMC) in the Netherlands. He completed his PhD in 1988 (cum laude) on "Interleukin-1 , a regulator of hematopoiesis" and later became Head of Bone Marrow Transplantation and the Department of Immunohematology. He has held various leadership roles at LUMC, was president of the European Hematology Association (EHA) and served on committees for the EMA, WHO, ISEH, NetCord and ASH. He is an active member of the Netherlands Clinical Trial Competent Authority. Dr. Fibbe's research focuses on hematopoietic stem cell biology, regenerative medicine, and cellular therapies. He co-founded the Leiden Regenerative Medicine Platform and is CSO of Starfish Innovations. In 2018, he was named Knight in the Order of the Lion of the Netherlands.
Deputy Editor
Caron Jacobson, MDDana-Farber Cancer Institute
Boston, Massachusetts
Caron Jacobson is an Associate Professor of Medicine at Harvard Medical School, Senior Physician in the lymphoma division at the Dana-Farber Cancer Institute, and the Medical Director of the Immune Effector Cell (IEC) Therapy Program at the Dana-Farber Cancer Institute. She earned her BS from Brown University and MD from Columbia College of Physicians and Surgeons, where she stayed to do her Internal Medicine Residency and Chief Residency before completing her fellowship in hematology and oncology at the joint Dana-Farber/Massachusetts General fellowship program. She is a lymphoma clinical investigator with a focus on cellular immunotherapy for the treatment of lymphoma, and has led several industry-sponsored and investigator-initiated trials of CAR T-cells in lymphoma. As the Medical Director of the IEC program, she oversees both the commercial and research efforts in engineered cellular therapies across the institute, from blood cancers to solid tumors.
Advertisement intended for health care professionals
